Portfolio

Bial
Pharmaceutical
EGF II | EGF III | EGF IV

Invested in
2021

INVESTMENT RATIONALE

Important National company in the pharmaceutical sector, standing out for its innovation and development in the production of medicines to contribute towards the improvement of people’s quality of life.

STRATEGY

Continuous development of new medicines, strengthening of production capacity, including the construction of a new antibiotic production unit.

Please note, your browser is out of date.
For a good browsing experience we recommend using the latest version of Chrome, Firefox, Safari, Opera or Internet Explorer.